90 related articles for article (PubMed ID: 25183193)
1. Genetically detoxified pertussis toxin (PT-9K/129G): implications for immunization and vaccines.
Seubert A; D'Oro U; Scarselli M; Pizza M
Expert Rev Vaccines; 2014 Oct; 13(10):1191-204. PubMed ID: 25183193
[TBL] [Abstract][Full Text] [Related]
2. The History of Pertussis Toxin.
Locht C; Antoine R
Toxins (Basel); 2021 Sep; 13(9):. PubMed ID: 34564627
[TBL] [Abstract][Full Text] [Related]
3. Confocal microscopy study of pertussis toxin and toxoids on CHO-cells.
Tan Y; Fleck RA; Asokanathan C; Yuen CT; Xing D; Zhang S; Wang J
Hum Vaccin Immunother; 2013 Feb; 9(2):332-8. PubMed ID: 23291938
[TBL] [Abstract][Full Text] [Related]
4. Long-lived immunity to genetically detoxified pertussis vaccines.
Locht C
EClinicalMedicine; 2021 Jul; 37():101014. PubMed ID: 34278279
[No Abstract] [Full Text] [Related]
5. Caspase-1-independent interleukin-1β is required for clearance of Bordetella pertussis infections and whole-cell vaccine-mediated immunity.
Place DE; Muse SJ; Kirimanjeswara GS; Harvill ET
PLoS One; 2014; 9(9):e107188. PubMed ID: 25198773
[TBL] [Abstract][Full Text] [Related]
6. Identification of linear B epitopes of pertactin of Bordetella pertussis induced by immunization with whole and acellular vaccine.
da Silva FR; Napoleão-Pego P; De-Simone SG
Vaccine; 2014 Oct; 32(47):6251-8. PubMed ID: 25252193
[TBL] [Abstract][Full Text] [Related]
7. Pertactin-negative Bordetella pertussis strains in Canada: characterization of a dozen isolates based on a survey of 224 samples collected in different parts of the country over the last 20 years.
Tsang RS; Shuel M; Jamieson FB; Drews S; Hoang L; Horsman G; Lefebvre B; Desai S; St-Laurent M
Int J Infect Dis; 2014 Nov; 28():65-9. PubMed ID: 25244999
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the key antigenic components of pertussis vaccine based on outer membrane vesicles.
Ormazábal M; Bartel E; Gaillard ME; Bottero D; Errea A; Zurita ME; Moreno G; Rumbo M; Castuma C; Flores D; Martín MJ; Hozbor D
Vaccine; 2014 Oct; 32(46):6084-90. PubMed ID: 25240753
[TBL] [Abstract][Full Text] [Related]
9. A novel TLR2 agonist from Bordetella pertussis is a potent adjuvant that promotes protective immunity with an acellular pertussis vaccine.
Dunne A; Mielke LA; Allen AC; Sutton CE; Higgs R; Cunningham CC; Higgins SC; Mills KH
Mucosal Immunol; 2015 May; 8(3):607-17. PubMed ID: 25315966
[TBL] [Abstract][Full Text] [Related]
10. Genetic Profile Variation in Vaccine Strains and Clinical Isolates of Bordetella pertussis Recovered from Iranian Patients.
Haghighi F; Shahcheraghi F; Abbasi E; Eshraghi SS; Zeraati H; Mousavi SA; Asgarian-Omran H; Douraghi M; Shokri F
Avicenna J Med Biotechnol; 2014 Jul; 6(3):178-84. PubMed ID: 25215182
[TBL] [Abstract][Full Text] [Related]
11. Identification of pertussis-specific effector memory T cells in preschool children.
de Rond L; Schure RM; Öztürk K; Berbers G; Sanders E; van Twillert I; Carollo M; Mascart F; Ausiello CM; van Els CA; Smits K; Buisman AM
Clin Vaccine Immunol; 2015 May; 22(5):561-9. PubMed ID: 25787136
[TBL] [Abstract][Full Text] [Related]
12. Pertussis in young infants: clinical presentation, course and prevention.
O'Riordan A; Cleary J; Cunney R; Nicholson AJ
Ir Med J; 2014; 107(7):217-9. PubMed ID: 25226721
[TBL] [Abstract][Full Text] [Related]
13. Anti-pertussis antibody kinetics following DTaP-IPV booster vaccination in Norwegian children 7-8 years of age.
Aase A; Herstad TK; Jørgensen SB; Leegaard TM; Berbers G; Steinbakk M; Aaberge I
Vaccine; 2014 Oct; 32(45):5931-6. PubMed ID: 25218299
[TBL] [Abstract][Full Text] [Related]
14. Impact of conjugation chemistry on the immunogenicity of S. Typhimurium conjugate vaccines.
Stefanetti G; Rondini S; Lanzilao L; Saul A; MacLennan CA; Micoli F
Vaccine; 2014 Oct; 32(46):6122-9. PubMed ID: 25192974
[TBL] [Abstract][Full Text] [Related]
15. Bordetella pertussis: an underreported pathogen in pediatric respiratory infections, a prospective cohort study.
van den Brink G; Wishaupt JO; Douma JC; Hartwig NG; Versteegh FG
BMC Infect Dis; 2014 Sep; 14():526. PubMed ID: 25267437
[TBL] [Abstract][Full Text] [Related]
16. Immune responses to pertussis antigens in infants and toddlers after immunization with multicomponent acellular pertussis vaccine.
Fadugba OO; Wang L; Chen Q; Halasa NB
Clin Vaccine Immunol; 2014 Dec; 21(12):1613-9. PubMed ID: 25253666
[TBL] [Abstract][Full Text] [Related]
17. Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine.
Hegerle N; Dore G; Guiso N
Vaccine; 2014 Nov; 32(49):6597-600. PubMed ID: 25312274
[TBL] [Abstract][Full Text] [Related]
18. Colonization of Bordetella pertussis clinical isolates that differ by pulsed field gel electrophoresis types in the lungs of naïve mice or mice immunized with the whole-cell pertussis vaccine used in Poland.
Polak M; Zawadka M; Mosiej E; Rabczenko D; Augustynowicz E; Guiso N; Lutyńska A
Arch Immunol Ther Exp (Warsz); 2015 Apr; 63(2):155-60. PubMed ID: 25297678
[TBL] [Abstract][Full Text] [Related]
19. The vaccine potential of Bordetella pertussis biofilm-derived membrane proteins.
de Gouw D; Serra DO; de Jonge MI; Hermans PW; Wessels HJ; Zomer A; Yantorno OM; Diavatopoulos DA; Mooi FR
Emerg Microbes Infect; 2014 Aug; 3(8):e58. PubMed ID: 26038752
[TBL] [Abstract][Full Text] [Related]
20. Pertussis models to inform vaccine policy.
Campbell PT; McCaw JM; McVernon J
Hum Vaccin Immunother; 2015; 11(3):669-78. PubMed ID: 25714499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
